Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 10/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | PRKCI | P41743 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | MPI | P34949 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.60 |
| ▸ | PTPRF | P10586 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190649 | 0.97 | PRKCZ (0.80) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL690278 | 0.89 | PRKCZ (0.84) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8289654 | 0.89 | PRKCZ (1.00) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL1554182 | 0.88 | PRKCZ (0.82) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL8290363 | 0.88 | PRKCZ (0.82) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL689204 | 0.86 | PRKCZ (1.00) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL3942905 | 0.86 | PRKCZ (0.68) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL689112 | 0.86 | PRKCZ (0.80) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL690269 | 0.86 | PRKCZ (1.00) | PRKCZALDH1A1HSD17B10HPGDPRKCI | |
| SCHEMBL5919183 | 0.86 | PRKCZ (0.67) | PRKCZALDH1A1HSD17B10HPGDPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PRKCZ 3336/4885ALDH1A1 1871/4885HSD17B10 1131/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | PRKCZ 4810/4885ALDH1A1 423/4885HSD17B10 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.